Pharmacokinetic evaluation of pramipexole

Angelo Antonini, Daniela Calandrella

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction: Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily administration and to provide more stable dopaminergic stimulation in PD patients. Areas covered: This review summarizes the overall pharmacokinetic profile of pramipexole for both the IR and ER formulations. Also discussed are the clinically relevant determinants of pramipexole peripheral pharmacokinetics and the potential role of genetic and clinical determinants in drug efficacy. Expert opinion: Pramipexole is a non-ergot agonist with selective affinity for dopamine receptors of the D2 subfamily, in particular D3. Pramipexole has a very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Furthermore, it does not carry the risk to induce valvular heart disease or pulmonary and retroperitoneal fibrosis, seen with long-term use of the ergot-derived dopamine agonists. The recent introduction of a once-daily formulation poses significant advantages for patients, reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages could include the opportunity to provide more continuous drug delivery in a fashion that could help minimize dyskinesia risk, if the drug is used early in the disease course.

Original languageEnglish
Pages (from-to)1307-1314
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume7
Issue number10
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Pharmacokinetics
Levodopa
Parkinson Disease
Receptor, Serotonin, 5-HT2B
Pharmaceutical Preparations
Retroperitoneal Fibrosis
Restless Legs Syndrome
Heart Valve Diseases
Dopamine D2 Receptors
Pulmonary Fibrosis
Dopamine Agonists
Dyskinesias
Expert Testimony
Drug delivery
Signs and Symptoms
pramipexole
Appointments and Schedules
Therapeutics
Plasmas

Keywords

  • Continuous drug delivery
  • Extended-release
  • Immediate-release
  • Pharmacokinetic
  • Pramipexole

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Pharmacokinetic evaluation of pramipexole. / Antonini, Angelo; Calandrella, Daniela.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, No. 10, 10.2011, p. 1307-1314.

Research output: Contribution to journalArticle

Antonini, Angelo ; Calandrella, Daniela. / Pharmacokinetic evaluation of pramipexole. In: Expert Opinion on Drug Metabolism and Toxicology. 2011 ; Vol. 7, No. 10. pp. 1307-1314.
@article{29f4801d940c4278928abc717f691b3a,
title = "Pharmacokinetic evaluation of pramipexole",
abstract = "Introduction: Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily administration and to provide more stable dopaminergic stimulation in PD patients. Areas covered: This review summarizes the overall pharmacokinetic profile of pramipexole for both the IR and ER formulations. Also discussed are the clinically relevant determinants of pramipexole peripheral pharmacokinetics and the potential role of genetic and clinical determinants in drug efficacy. Expert opinion: Pramipexole is a non-ergot agonist with selective affinity for dopamine receptors of the D2 subfamily, in particular D3. Pramipexole has a very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Furthermore, it does not carry the risk to induce valvular heart disease or pulmonary and retroperitoneal fibrosis, seen with long-term use of the ergot-derived dopamine agonists. The recent introduction of a once-daily formulation poses significant advantages for patients, reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages could include the opportunity to provide more continuous drug delivery in a fashion that could help minimize dyskinesia risk, if the drug is used early in the disease course.",
keywords = "Continuous drug delivery, Extended-release, Immediate-release, Pharmacokinetic, Pramipexole",
author = "Angelo Antonini and Daniela Calandrella",
year = "2011",
month = "10",
doi = "10.1517/17425255.2011.614232",
language = "English",
volume = "7",
pages = "1307--1314",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetic evaluation of pramipexole

AU - Antonini, Angelo

AU - Calandrella, Daniela

PY - 2011/10

Y1 - 2011/10

N2 - Introduction: Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily administration and to provide more stable dopaminergic stimulation in PD patients. Areas covered: This review summarizes the overall pharmacokinetic profile of pramipexole for both the IR and ER formulations. Also discussed are the clinically relevant determinants of pramipexole peripheral pharmacokinetics and the potential role of genetic and clinical determinants in drug efficacy. Expert opinion: Pramipexole is a non-ergot agonist with selective affinity for dopamine receptors of the D2 subfamily, in particular D3. Pramipexole has a very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Furthermore, it does not carry the risk to induce valvular heart disease or pulmonary and retroperitoneal fibrosis, seen with long-term use of the ergot-derived dopamine agonists. The recent introduction of a once-daily formulation poses significant advantages for patients, reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages could include the opportunity to provide more continuous drug delivery in a fashion that could help minimize dyskinesia risk, if the drug is used early in the disease course.

AB - Introduction: Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily administration and to provide more stable dopaminergic stimulation in PD patients. Areas covered: This review summarizes the overall pharmacokinetic profile of pramipexole for both the IR and ER formulations. Also discussed are the clinically relevant determinants of pramipexole peripheral pharmacokinetics and the potential role of genetic and clinical determinants in drug efficacy. Expert opinion: Pramipexole is a non-ergot agonist with selective affinity for dopamine receptors of the D2 subfamily, in particular D3. Pramipexole has a very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Furthermore, it does not carry the risk to induce valvular heart disease or pulmonary and retroperitoneal fibrosis, seen with long-term use of the ergot-derived dopamine agonists. The recent introduction of a once-daily formulation poses significant advantages for patients, reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages could include the opportunity to provide more continuous drug delivery in a fashion that could help minimize dyskinesia risk, if the drug is used early in the disease course.

KW - Continuous drug delivery

KW - Extended-release

KW - Immediate-release

KW - Pharmacokinetic

KW - Pramipexole

UR - http://www.scopus.com/inward/record.url?scp=80053032491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053032491&partnerID=8YFLogxK

U2 - 10.1517/17425255.2011.614232

DO - 10.1517/17425255.2011.614232

M3 - Article

C2 - 21892895

AN - SCOPUS:80053032491

VL - 7

SP - 1307

EP - 1314

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 10

ER -